Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic Interventions
MITI aims to develop advanced non-invasive metabolic imaging technology for early disease detection and therapy effectiveness assessment, improving patient outcomes and reducing healthcare costs.
Projectdetails
Introduction
MITI will develop and mature a novel, ground-breaking technology for high precision non-ionizing metabolic imaging, enabling fast and non-invasive detection of the markers of metabolic processes e.g., cell proliferation and energy metabolism.
Benefits of the Technology
Using the results of metabolic imaging, medical specialists will be able to establish the effectiveness of therapies and determine the specific disease months sooner than is possible with currently available technologies. This will increase patient well-being and reduce the costs of healthcare as unsuccessful therapies can be stopped and replaced earlier by more effective (personalized) therapies.
Market Potential
This solution addresses an enormous market with millions of patients worldwide. MITI builds on the results of NICI in which the basic key marker molecules for metabolic imaging on MRI platforms were successfully discovered (1H, 2H, 31P, and 23Na), including the capability to detect these by inserts on 7T MRI platforms.
Project Components
MITI comprises:
- The further development and testing of a basic double tuned metabolic imaging set (detecting 1H and one of the following molecules: 2H, 31P, or 23Na).
- Validation of the basic technology to detect metabolic markers in specific use cases:
- Cell proliferation metabolism after treatment of lung tumors and pancreatic cancer with liver metastases.
- Cardiac drug mechanisms.
- Energy metabolism of muscle dystrophy.
- Development of an advanced quadruple tuned metabolic imaging set that will broaden the spectrum of metabolic processes that can be successfully viewed in parallel.
Future Plans
The results of the use cases will be used for power calculations for clinical trials to be conducted after MITI. The MITI partners aim to commercialize the technology, directly after MITI by providing it to clinicians in research centers and within 3 years after MITI to general medical centers.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.100.238 |
Totale projectbegroting | € 2.100.238 |
Tijdlijn
Startdatum | 1-4-2022 |
Einddatum | 30-9-2025 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- UNIVERSITAIR MEDISCH CENTRUM UTRECHTpenvoerder
- TESLA DYNAMIC COILS BV
- Fondazione Stella Maris
- UNIVERSITAETSKLINIKUM ESSEN
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Land(en)
Vergelijkbare projecten binnen EIC Transition
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
MIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic careMIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally. | EIC Transition | € 2.495.127 | 2022 | Details |
Early detection of treatment response in breast cancerThe project aims to enhance breast cancer treatment through Hyperpolarized Magnetic Resonance imaging for early detection of non-responders, improving outcomes and reducing side effects. | EIC Transition | € 2.499.229 | 2024 | Details |
Truly portable MRI for extremity and brain imaging anywhere & everywhereThe NextMRI project aims to develop portable low-field MRI systems for accessible point-of-care imaging, enhancing diagnostic capabilities and usability for underserved populations globally. | EIC Transition | € 2.494.415 | 2023 | Details |
Magnetic Resonance at the Scale of a CellThe HyperCell project aims to revolutionize cell research by developing a non-invasive benchtop tool for single-cell metabolic analysis, enhancing understanding of diseases and treatment responses. | EIC Transition | € 1.998.750 | 2024 | Details |
MIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic care
MIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally.
Early detection of treatment response in breast cancer
The project aims to enhance breast cancer treatment through Hyperpolarized Magnetic Resonance imaging for early detection of non-responders, improving outcomes and reducing side effects.
Truly portable MRI for extremity and brain imaging anywhere & everywhere
The NextMRI project aims to develop portable low-field MRI systems for accessible point-of-care imaging, enhancing diagnostic capabilities and usability for underserved populations globally.
Magnetic Resonance at the Scale of a Cell
The HyperCell project aims to revolutionize cell research by developing a non-invasive benchtop tool for single-cell metabolic analysis, enhancing understanding of diseases and treatment responses.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Spatial Quantification of Cellular Metabolism in the Tumor Immune MicroenvironmentThis project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment. | ERC Starting... | € 1.497.756 | 2023 | Details |
Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRIDevelop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics. | ERC Starting... | € 1.497.669 | 2024 | Details |
Hyperpolarized Magnetic Resonance at the point-of-careHYPMET aims to revolutionize personalized cancer treatment by developing a compact NMR technology for real-time monitoring of metabolic pathways and body fluid analyses using enhanced hyperpolarization methods. | ERC Starting... | € 1.499.968 | 2024 | Details |
REAL TIME MOLECULAR IMAGER WITH UNSURPASSED RESOLUTIONRETIMAGER aims to revolutionize PET imaging by achieving ten-fold improvements in spatial and temporal resolution, enabling real-time, high-sensitivity imaging for personalized precision medicine. | EIC Pathfinder | € 3.126.347 | 2023 | Details |
Revealing liver micrometastases in vivo using ultra-high definition MRIMicroMetSCAN aims to revolutionize MRI techniques for early detection of liver micrometastases, enhancing cancer diagnosis and treatment through improved imaging sensitivity and biological insights. | ERC Starting... | € 1.998.456 | 2025 | Details |
Spatial Quantification of Cellular Metabolism in the Tumor Immune Microenvironment
This project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment.
Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRI
Develop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics.
Hyperpolarized Magnetic Resonance at the point-of-care
HYPMET aims to revolutionize personalized cancer treatment by developing a compact NMR technology for real-time monitoring of metabolic pathways and body fluid analyses using enhanced hyperpolarization methods.
REAL TIME MOLECULAR IMAGER WITH UNSURPASSED RESOLUTION
RETIMAGER aims to revolutionize PET imaging by achieving ten-fold improvements in spatial and temporal resolution, enabling real-time, high-sensitivity imaging for personalized precision medicine.
Revealing liver micrometastases in vivo using ultra-high definition MRI
MicroMetSCAN aims to revolutionize MRI techniques for early detection of liver micrometastases, enhancing cancer diagnosis and treatment through improved imaging sensitivity and biological insights.